Bharat Biotech has submitted Phase 3 clinical trial data for its Covid-19 vaccine, Covaxin, to the Drug Controller General of India (DCGI). The development comes nearly five months after Covaxin was authorised for emergency usage in the country. <br /> <br />The DCGI’s Subject Expert Committee will take up the matter today. The meeting to review Phase 3 data of Covaxin, the country's first fully homegrown Covid vaccine, will commence at noon. <br /> <br />The Hyderabad-based vaccine maker had stated that its coronavirus vaccine was 81 per cent effective in preventing the infection, according to early analysis of the results from late-stage trials.
